Top Story

Nitrogenous bisphosphonate use may reduce risk for endometrial cancer

December 22, 2014

Exposure to nitrogenous bisphosphonates appeared to have a protective effect on the incidence of endometrial cancer in women who never had the malignancy, according to study results.

“Other studies have shown that bisphosphonates may reduce the risk of certain cancers, but we are the first to show that the risk for endometrial cancer may also be reduced,” researcher Sharon Hensley Alford, PhD, of the Henry Ford Health System, said in a press release. “This study suggests that women who need bone strengthening medications and who have increased risk for endometrial cancer may want to choose the nitrogen form of bisphosphonates because this form may reduce the risk of endometrial cancer.”

Deborah Young In the JournalsPerspective

Self-reported exercise assessments offer clue to cardiometabolic risks

December 22, 2014
Clinicians could glean additional information about patients’ cardiometabolic risk factors through routine clinical physical activity assessments, according to…

Neurocrine Biosciences launches trial for congenital adrenal hyperplasia therapy

December 21, 2014
After completing a pilot clinical trial in adults with classic congenital adrenal hyperplasia, Neurocrine Biosciences, Inc. announced a trial for its…

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

Lower risk for type 2 diabetes among people with type O blood

December 19, 2014
People with the blood types A, B and AB have a higher risk for developing type 2 diabetes than those with type O, according to recent study findings published in…
More News Headlines »
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Meeting News Coverage Video
thumbnail for video 3890508474001

Lenvatinib, sorafenib may significantly impact treatment of differentiated thyroid cancer

November 13, 2014
Marcia S. Brose, MD, PhD, associate professor at the University of Pennsylvania and director of the thyroid cancer…
More »
Acromegaly Cases

Acromegaly Cases: Expert Insights into Diagnosis and Emerging Treatment Options – Part 5 of 5

This activity is supported by an educational grant from Genentech.

Acromegaly is a rare chronic disorder that is typically caused by excessive growth hormone secretion, and is…
More »